What You Need To Know Ahead of Eli Lilly Earnings
As pharmaceutical giant Eli Lilly (LLY) plans to report third-quarter earnings Wednesday morning, analysts are focused on the production and sales of Mounjaro and Zepbound—two popular weight-loss d...
Lilly's mirikizumab is first and only IL23p19 antagonist to report long-term, multi-year, sustained efficacy and safety data for both ulcerative co...
At three years, over 80% of patients with moderately to severely active UC who were in remission with mirikizumab sustained long-term remission and relief from disruptive symptoms, including bowel ...
ViaNautis Bio Signs Strategic Collaboration Agreement with Lilly to leverage its polyNaut® platform to develop novel products delivering genetic me...
ViaNautis Bio Signs Strategic Collaboration Agreement with Lilly to leverage its polyNaut® platform to develop novel products delivering genetic medicines
Eli Lilly gets nod to launch weight-loss drug in Hong Kong - Bloomberg News
Eli Lilly expects to start selling its weight-loss drug in Hong Kong as early as the end of this year, Bloomberg News reported on Sunday.
Billionaire Stanley Druckenmiller Closed Out His Position in Eli Lilly Stock. 3 Reasons Why I'm Still a Buyer.
Stanley Druckenmiller's Duquesne Family Office exited its position in Eli Lilly stock last quarter.
2 Soaring Growth Stocks That Are Still Worth Buying
These two companies -- leaders in their industries -- look unstoppable.
Lilly's EBGLYSS™ (lebrikizumab-lbkz) demonstrated meaningful improvement in skin clearance and itch relief in the majority of patients with moderat...
In first dedicated study of a selective IL-13 inhibitor in patients previously treated with dupilumab, the majority of patients had a history of inadequate response to dupilumab EBGLYSS also provid...
Is Lilly Stock a Portfolio Must Have Ahead of its Q3 Earnings?
Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines Mounjaro and Zepbound.
Lilly's Alzheimer's drug approved in the UK
UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved Eli Lilly's treatment for early Alzheimer's, the company said on Wednesday.
This Setback for Johnson & Johnson Is 1 More Green Light for Eli Lilly's Stock
Fewer contenders means fewer constraints on expanding market share.
MangoRx Responds to and Refutes Recent Claims Made by Eli Lilly
Dallas, Texas, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men's health and wellness ...
Lilly sues online vendors, medical spa over copycat weight-loss drugs
Eli Lilly said on Monday it sued three medical spas and online vendors for selling products claiming to contain tirzepatide, the main ingredient in its popular weight-loss medicine Zepbound, includ...
Eli Lilly Buy On Weakness Signal (Technical Analysis)
Eli Lilly has triggered multiple Buy signals, including Timing, SAR, and Fundamental, with a 12-month target of ~$1,150. Technical indicators like Full Stochastic, Chaikin money flow, and ADX Deman...
1 Reason to Buy Eli Lilly Stock Hand Over Fist Right Now
Eli Lilly just secured a huge win, and it's not related to the weight loss industry.
Eli Lilly vs. Novo Nordisk: Which Weight Loss Stock is The Better Opportunity Over The Next 10 Years?
These are two of healthcare's biggest darlings right now, but one looks better positioned for the long run.
Related Companies